Journal
JOURNAL OF CONTROLLED RELEASE
Volume 250, Issue -, Pages 48-61Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.02.009
Keywords
Perlecan; Proteoglycan; Vascular endothelial growth factor; Chitosan; Wound healing; Skin tissue engineering
Funding
- NIAMS NIH HHS [R43 AR061204] Funding Source: Medline
Ask authors/readers for more resources
The repair of dermal wounds, particularly in the diabetic population, poses a significant healthcare burden. The impaired wound healing of diabetic wounds is attributed to low levels of endogenous growth factors, including vascular endothelial growth factor (VEGF), that normally stimulate multiple phases of wound healing. In this study, chitosan scaffolds were prepared via freeze drying and loaded with plasmid DNA encoding perlecan domain I and VEGF189 and analyzed in vivo for their ability to promote dermal wound healing. The plasmid DNA encoding perlecan domain I and VEGF189 loaded scaffolds promoted dermal wound healing in normal and diabetic rats. This treatment resulted in an increase in the number of blood vessels and sub-epithelial connective tissue matrix components within the wound beds compared to wounds treated with chitosan scaffolds containing control DNA orwounded controls. These results suggest that chitosan scaffolds containing plasmidDNA encoding VEGF189 and perlecan domain I have the potential to induce angiogenesis and wound healing. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available